Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine
Pharmaceutical Technology
OCTOBER 28, 2022
The company says that these four serotypes represent roughly 10–15% of bacteria causing pneumococcal disease in adults. Pneumococcal vaccines are used to inoculate individuals against infections caused by the Streptococcus pneumoniae bacteria. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.
Let's personalize your content